OTCMKTS:PMCB - Pharmacyte Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0393 0.00 (0.00 %) (As of 05/19/2019 06:29 AM ET)Previous Close$0.0393Today's Range$0.0384 - $0.042052-Week Range$0.0350 - $0.1050Volume1.07 million shsAverage Volume1.81 million shsMarket Capitalization$45.51 millionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California. Receive PMCB News and Ratings via Email Sign-up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PMCB Previous Symbol CUSIPN/A CIK1157075 Webwww.pharmacytebiotech.com Phone917-595-2850Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book3.93Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,820,000.00 Net MarginsN/A Return on Equity-74.36% Return on Assets-66.54%Miscellaneous Employees4 Outstanding Shares1,158,010,000Market Cap$45.51 million Next Earnings Date7/19/2019 (Estimated) OptionableNot Optionable Pharmacyte Biotech (OTCMKTS:PMCB) Frequently Asked Questions What is Pharmacyte Biotech's stock symbol? Pharmacyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB." When is Pharmacyte Biotech's next earnings date? Pharmacyte Biotech is scheduled to release their next quarterly earnings announcement on Friday, July 19th 2019. View Earnings Estimates for Pharmacyte Biotech. Has Pharmacyte Biotech been receiving favorable news coverage? Media stories about PMCB stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pharmacyte Biotech earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. Who are some of Pharmacyte Biotech's key competitors? Some companies that are related to Pharmacyte Biotech include Gamida Cell (GMDA), Compugen (CGEN), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE), Neon Therapeutics (NTGN), Novavax (NVAX), Erytech Pharma (ERYP), Organovo (ONVO), Oncobiologics (ONS), Surface Oncology (SURF), INmune Bio (INMB), Allena Pharmaceuticals (ALNA), Nantkwest (NK), Champions Oncology (CSBR) and Pluristem Therapeutics (PSTI). What other stocks do shareholders of Pharmacyte Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmacyte Biotech investors own include Cronos Group (CRON), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Cannabis Science (CBIS), mCig (MCIG), Medical Marijuana (MJNA), OrganiGram (OGRMF), GW Pharmaceuticals PLC- (GWPH), NVIDIA (NVDA) and KushCo (KSHB). Who are Pharmacyte Biotech's key executives? Pharmacyte Biotech's management team includes the folowing people: Mr. Kenneth L. Waggoner, Chairman, CEO, Pres, Gen. Counsel & Sec. (Age 71)Mr. Carlos A. Trujillo, CFO & Director (Age 61)Dr. Gerald W. Crabtree, COO & Director (Age 78)Prof. Walter H. Günzburg, Chief Scientific Officer & Consultant (Age 60)Dr. Mark L. Rabe, Director of Cannabis Program Devel. and Member of Medical & Scientific Advisory Board How do I buy shares of Pharmacyte Biotech? Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pharmacyte Biotech's stock price today? One share of PMCB stock can currently be purchased for approximately $0.0393. How big of a company is Pharmacyte Biotech? Pharmacyte Biotech has a market capitalization of $45.51 million. Pharmacyte Biotech employs 4 workers across the globe. What is Pharmacyte Biotech's official website? The official website for Pharmacyte Biotech is http://www.pharmacytebiotech.com. How can I contact Pharmacyte Biotech? Pharmacyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The company can be reached via phone at 917-595-2850 or via email at [email protected] MarketBeat Community Rating for Pharmacyte Biotech (OTCMKTS PMCB)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 203 (Vote Underperform)Total Votes: 385MarketBeat's community ratings are surveys of what our community members think about Pharmacyte Biotech and other stocks. Vote "Outperform" if you believe PMCB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMCB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Intrinsic Value Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.